{'fraction_non_alphanumeric': 0.0258751902587519, 'fraction_numerical': 0.0076103500761035, 'mean_word_length': 5.783505154639175, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Lipid Phosphate Phosphatase 3 regulates Lysophosphatidic Acid mediated vascular response in diabetic vascular injury

Single nucleotide polymorphism in the PLPP3 gene is associated with the risk of coronary artery disease (CAD). PLPP3 encodes the lipid phosphate phosphatases (LPP) 3 that degrades and thereby attenuates lysophosphatidic acid (LPA) responsiveness of cells. Recently, LPA has been purposed to serve as a ligand for RAGE (Receptor for Advanced Glycation End Products), leading to diabetes associated with vascular dysfunction. However, a pathophysiologic role of LPP3 in diabetic vascular smooth muscle cells (VSMC) remains to be established.